Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1

Interventions

Magnetic Resonance Spectroscopy 51Specimen Handling 42enzalutamide 35Androgen Antagonists 34Radiosurgery 32Radiotherapy 31Prednisone 26darolutamide 24Abiraterone Acetate 24Leuprolide 22Docetaxel 22apalutamide 20Pluvicto 19abiraterone 18Standard of Care 18Triptorelin Pamoate 17Radiation 17Biopsy 16relugolix 15acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 14Blood Specimen Collection 13gallium 68 PSMA-11 12pembrolizumab 11X-Rays 11Surveys and Questionnaires 11luprolide acetate gel depot 10Carboplatin 10Methods 9Interviews as Topic 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Prostatic Neoplasms × tazemetostat × Clear all
NCT07407283 2026-04-21

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Recruiting
100 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡